Clinical trial
A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's…
NCT00001439 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00001439 |
|---|---|
| Title | A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant |
| Official title | A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Biological |
| Interventions | gp100 human melanoma peptide |
| Enrollment | 255 |
| Start date | Jun 1, 1995 |
| Completion | Apr 1, 2000 |
| First posted | Dec 10, 2002 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: